Hematology and oncology pharmacists discussed patient outreach at a panel during the Hematology/Oncology Pharmacy Association’s (HOPA) annual conference in April.
As the cost of treating the disease has risen, so too have the direct medical care expenses that patients pay out of pocket, as commercial insurers increasingly shift the burden of paying for treatment to patients through higher premiums, deductibles, and co-pays.
Despite advances in cancer care, patients typically face obstacles to treatment.
During a presentation at the recent Community Oncology Alliance Annual Conference in Orlando, Florida, Ray Bailey, RPh, discussed the implications of medical marijuana for patients with cancer.
Health-system–owned and operated specialty pharmacies have become a trend to not only capture previously unrealized profit but to also close the gap between provider, patient, and medication.
Researchers have found that methylnaltrexone, a peripherally acting µ-opioid receptor antagonist, may offer an effective solution to relieving patients' opioid-induced constipation with minimal adverse effects.
The FDA approval of pembrolizumab plus lenvatinib for this new indication is the first under a new international collaboration with Australia and Canada.
Two phase 3 studies showed that ofatumumab was superior to teriflunomide (Aubagio) in patients with relapsing forms of multiple sclerosis.
Research demonstrates a new direction in cell signaling and treatment for chronic inflammatory diseases such as psoriasis, asthma, and HIV.
The annual National Association of Specialty Pharmacy annual meeting shed light on the significant role these caregivers play in patient care.
The significant jump in hospital-owned specialty pharmacies bolsters the belief that health system leaders increasingly understand how these services enable their organizations to enhance patient care and achieve market differentiation.
The parties included in this agreement in principle represent some of the more than 2,600 lawsuits filed against Purdue Pharma concerning opioids, including the company’s OxyContin products.